BridgeBio Pharma ROE 2018-2026 | BBIO
Current and historical return on equity (ROE) values for BridgeBio Pharma (BBIO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| BridgeBio Pharma ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-03-31 | $-0.72B | $-2.01B | 35.90% |
| 2025-12-31 | $-0.73B | $-1.85B | 39.11% |
| 2025-09-30 | $-0.80B | $-1.70B | 46.90% |
| 2025-06-30 | $-0.78B | $-1.52B | 50.94% |
| 2025-03-31 | $-0.67B | $-1.35B | 49.43% |
| 2024-12-31 | $-0.54B | $-1.20B | 44.62% |
| 2024-09-30 | $-0.44B | $-1.17B | 37.43% |
| 2024-06-30 | $-0.45B | $-1.16B | 38.91% |
| 2024-03-31 | $-0.54B | $-1.23B | 43.70% |
| 2023-12-31 | $-0.64B | $-1.28B | 50.42% |
| 2023-09-30 | $-0.61B | $-1.25B | 49.03% |
| 2023-06-30 | $-0.57B | $-1.23B | 46.45% |
| 2023-03-31 | $-0.43B | $-1.15B | 36.97% |
| 2022-12-31 | $-0.48B | $-1.11B | 43.47% |
| 2022-09-30 | $-0.49B | $-1.01B | 48.40% |
| 2022-06-30 | $-0.51B | $-0.92B | 55.61% |
| 2022-03-31 | $-0.60B | $-0.78B | 76.68% |
| 2021-12-31 | $-0.56B | $-0.61B | 91.68% |
| 2021-09-30 | $-0.54B | $-0.37B | 144.69% |
| 2021-06-30 | $-0.50B | $-0.13B | 377.86% |
| 2021-03-31 | $-0.52B | $0.07B | -803.09% |
| 2020-12-31 | $-0.45B | $0.27B | -163.72% |
| 2020-09-30 | $-0.40B | $0.37B | -109.76% |
| 2020-06-30 | $-0.35B | $0.44B | -78.15% |
| 2020-03-31 | $-0.29B | $0.36B | -80.55% |
| 2019-12-31 | $-0.26B | $0.25B | -104.42% |
| 2019-06-30 | $-0.16B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |